<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский вестник Юга России</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Herald of the South of Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2023-14-4-58-65</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-1809</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АЛЛЕРГОЛОГИЯ И ИММУНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ALLERGOLOGY AND IMMUNOLOGY</subject></subj-group></article-categories><title-group><article-title>Система интерферонов при типичных хронических и атипично протекающих хронических активных герпесвирусных инфекциях</article-title><trans-title-group xml:lang="en"><trans-title>Interferon system in typical chronic and atypically occurring chronic active herpes virus infections</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8948-8983</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Халтурина</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Khalturina</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгения Олеговна Халтурина – к.м.н., доцент, доцент кафедры микробиологии, вирусологии и иммунологии им. ак. А.А. Воробьева</p><p>Москва</p></bio><bio xml:lang="en"><p>Evgeniya O. Khalturina – Cand. Sci. (Med.), Associate Professo Associated Professor of Microbiology, Virology and Immunology Department named after A.A.Vorobiev</p><p>Moscow</p></bio><email xlink:type="simple">jane_k@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5339-4504</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нестерова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nesterova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Вадимовна Нестерова – д.м.н., профессор, профессор кафедры клинической иммунологии, аллергологии и адаптологии ФНМО Медицинского института</p><p>Москва</p></bio><bio xml:lang="en"><p>Irina V. Nesterova – Dr. Sci. (Med.), Professor, Professor of the Department of Clinical Immunology</p><p>Moscow</p></bio><email xlink:type="simple">nesterova1@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малиновская</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malinovskaya</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валентина Васильевна Малиновская – д.б.н., профессор, руководитель лаборатории онтогенеза и коррекции системы интерферона</p><p>Москва</p></bio><bio xml:lang="en"><p>Valentina V. Malinovskaya – Cand. Sci. (Bio.), Professor, Head of the Laboratory of Ontogenesis and Correction of the Interferon System</p><p>Moscow</p></bio><email xlink:type="simple">info@viferon.su</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4455-1050</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мяндиев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Myandiev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Морис Садикович Мяндиев – к.м.н., ассистент кафедрыпропедевтики стоматологических заболеваний</p><p>Москва</p></bio><bio xml:lang="en"><p>Maurice S. Myandiev – Cand. Sci. (Med.), Assistant, Department of Propaedeutics of Dental Diseases</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Российский университет дружбы народов</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный исследовательский центр эпидемиологии и микробиологии им. почётного академика Н.Ф. Гамалеи</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Centre for Epidemiology and Microbiology N.F. Gamaleya</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2023</year></pub-date><volume>14</volume><issue>4</issue><fpage>58</fpage><lpage>65</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Халтурина Е.О., Нестерова И.В., Малиновская В.В., Мяндиев М.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Халтурина Е.О., Нестерова И.В., Малиновская В.В., Мяндиев М.С.</copyright-holder><copyright-holder xml:lang="en">Khalturina E.O., Nesterova I.V., Malinovskaya V.V., Myandiev M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/1809">https://www.medicalherald.ru/jour/article/view/1809</self-uri><abstract><sec><title>Цель</title><p>Цель: изучение особенностей функционирования системы IFN, наличие аутоантител к INFα у пациентов, страдающих атипичными хроническими активными герпесвирусными инфекциями (АХА-ГВИ) в сравнении с пациентами, имеющими типичное течение хронических герпесвирусных инфекций (ХГВИ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: под наблюдением находились 485 пациентов обоего пола, от 23 до 70 лет, страдающих хроническими герпесвирусными инфекциями (335 пациентов – с АХА-ГВИ, 150 – с ХГВИ). Группа сравнения – 250 условно здоровых лиц (ГС). В комплекс исследования были включены методы детекции герпесвирусов: серодиагностика, PCR-RT. Методом ИФА было проведено исследование системы IFN (спонтанная и индуцированная продукция, сывороточная концентрация). Исследование было одобрено комиссией по вопросам этики, все пациенты дали информированное согласие.</p></sec><sec><title>Результаты</title><p>Результаты: определена частота встречаемости различных моно- и микстгерпесвирусных инфекций у пациентов с АХА-ГВИ (моно – 26,6%; микст – 73,4%) и ХГВИ (моно – 23,1%; микст – 76,9%), при этом показано доминирование ВЭБ у пациентов обеих групп. Выявлен дефицит сывороточного IFNα в 100% случаев в обеих группах, а IFNγ – в 67% при АХА-ГВИ и 57% – при ХГВИ. В то же время выявлены значительные достоверные различия между группами АХА-ГВИ и ХГВИ по уровню снижения IFNα (10 и в 5 раз соответственно), а для IFNγ – в 2,0 и в 2,6 раз соответственно. Показано снижение индуцированной продукции IFNα при АХА-ГВИ в 89,1% и в 47,2% (при ХГВИ). Снижение индуцированной продукции IFNγ характерно для 50% пациентов обеих групп. При этом уровень индуцированной продукции IFNα у пациентов с АХА-ГВИ был в 9 раз ниже, чем в группе контроля, и в 4,75 раза ниже, чем в группе пациентов с ХГВИ. А уровень индуцированной продукции IFNγ был в 2 раза ниже по сравнению с ХГВИ и группой контроля.</p></sec><sec><title>Выводы</title><p>Выводы: при оценке состояния системы ИФН у пациентов с различными хроническими герпесвирусными инфекциями выявлены значительные различия. Так, наиболее выраженные проявления интерферонопатии, заключающееся в значительном снижении сывороточных IFNα и IFNγ и дефектах индуцированной продукции IFN обоих типов, наблюдаются статистически достоверно чаще в группе пациентов с атипичным течением болезни, чем в группе пациентов с типичным течением ХГВИ. Наиболее выраженные нарушения в системе IFN и отсутствие восстановления уровней IFNα и IFNγ в межрецидивный период обусловливают атипичность течения и активную вирусную репликацию у пациентов с АХА-ГВИ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to study the characteristics of the functioning of the IFN system, the presence of autoantibodies to INFα in patients suffering from atypical chronic active herpesvirus infections (ACA-HVI) in comparison with patients with a typical course of chronic herpesvirus infections (CHVI).</p></sec><sec><title>Materials and methods</title><p>Materials and methods: under our supervision were 485 patients of both sexes aged 23 to 70 years, suffering from chronic herpes virus infections, of which 335 patients suffered from AHA-HVI and 150 people suffered from CHVI. The comparison group was 250 conditionally healthy individuals (CG). The complex of the study included methods for detecting herpesviruses: serodiagnostics, PCR-RT. The IFN system (spontaneous and induced production, serum concentration) was tested by ELISA. The study was approved by the ethics board and informed consent was obtained from all patients.</p></sec><sec><title>Results</title><p>Results: the incidence of various mono-mixed herpesvirus infections in patients with ACA-HVI (mono – 26,6% and mixed – 73.4%) and CHVI (mono – 23.1% and mixed – 76.9%) was determined, with EBV dominance in patients of both groups. Serum IFNα deficiency was detected in 100% of cases in both groups, and IFNα in 67% in ACA-HVI and 57% in CHVI. At the same time, significant differences were found between the ACA-HVI and HGVI groups in the level of IFNα reduction: 10 and 5 times, respectively, and for IFNγ – 2.0 and 2.6 times, respectively. The induced IFNα production decreased by 89.1% in ACA-HVI and 47.2% in CHVI. A decrease in induced IFNγ production is characteristic of 50% of patients in both groups. At the same time, the level of induced production of IFN α in patients with ACA-HVI was 9 times lower than in the control group and 4.75 times lower than in the group of patients with CHVI. And the level of induced IFNγ production was 2 times lower compared to CHVI and the control group.</p></sec><sec><title>Conclusions</title><p>Conclusions: when assessing the state of the IFN system in patients with various chronic herpes virus infections, significant differences were revealed. Thus, the most pronounced manifestations of interferonopathy, consisting in a significant decrease in serum IFNα and IFNγ and defects in induced IFN production of both types, are observed statistically significantly more often in the group of patients with an atypical course of the disease than in the group of patients with a typical course of CHVI. The most pronounced disorders in the IFN system and the lack of recovery of IFNα and IFNγ levels in the interrelational period cause atypicity of the course and active viral replication in patients with ACA-HVI.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>герпесвирусные инфекции</kwd><kwd>интерферонопатии</kwd><kwd>система интерферона</kwd></kwd-group><kwd-group xml:lang="en"><kwd>herpesvirus infections</kwd><kwd>interferon system</kwd><kwd>interferonopathy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Дюдюн А.Д., Полион Н.Н., Нагорный А.Е. Герпесвирусная инфекция. Клинико-иммунологические особенности. Клиническая лекция. Дерматовенерология. Косметология. Сексопатология. 2015;(3-4):119–125.</mixed-citation><mixed-citation xml:lang="en">Dyudyun A.D., Polyon N.M., Nagorny O.Ye. Herpesviral infection. The clinical and immunological features. A clinical lecture. Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2015;(3-4):119–125. (In Russ.) eLIBRARY ID: 26697236</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Горейко Т.В., Калинина Н.М., Дрыгина Л.Б. Современные представления об иммунопатогенезе инфекции, вызванной вирусом Эпштейна–Барр. Инфекция и иммунитет. 2014;1(2):121-130.</mixed-citation><mixed-citation xml:lang="en">Goreiko T.V., Kalinina N.M., Drygina L.V. The modern conceptions about immunopathogenesis of infection caused by the Epstein–Barr virus. Russian Journal of Infection and Immunity. 2014;1(2):121-130. https://doi.org/10.15789/2220-7619-2011-2-121-130</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Новикова И.А., Романива О.А. Особенности продукции цитокинов при рецидивирующей герпетической инфекции. Медицинская иммунология. 2013;15(6):571-576.</mixed-citation><mixed-citation xml:lang="en">Novikovа I.A., Romanivа O.A. Features of cytokine production in patients with recurrent herpetic infection. Medical Immunology (Russia). 2013;15(6):571-576. (In Russ.) https://doi.org/10.15789/1563-0625-2013-6-571-576</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HA. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71-81. https://doi.org/10.1016/j.cytogfr.2016.02.010</mixed-citation><mixed-citation xml:lang="en">Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HA. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71-81. https://doi.org/10.1016/j.cytogfr.2016.02.010</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 2009;37(Database issue):D852-7. https://doi.org/10.1093/nar/gkn732</mixed-citation><mixed-citation xml:lang="en">Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 2009;37(Database issue):D852-7. https://doi.org/10.1093/nar/gkn732</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun. 2017;83:1-11. https://doi.org/10.1016/j.jaut.2017.03.008</mixed-citation><mixed-citation xml:lang="en">Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun. 2017;83:1-11. https://doi.org/10.1016/j.jaut.2017.03.008</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fallet B, Narr K, Ertuna YI, Remy M, Sommerstein R, et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci Immunol. 2016;1(4):eaah6817. https://doi.org/10.1126/sciimmunol.aah6817</mixed-citation><mixed-citation xml:lang="en">Fallet B, Narr K, Ertuna YI, Remy M, Sommerstein R, et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci Immunol. 2016;1(4):eaah6817. https://doi.org/10.1126/sciimmunol.aah6817</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li W, Lv S, Liu G, Lu N, Jiang Y, et al. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma. Front Immunol. 2023;14:1124066. https://doi.org/10.3389/fimmu.2023.1124066</mixed-citation><mixed-citation xml:lang="en">Li W, Lv S, Liu G, Lu N, Jiang Y, et al. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma. Front Immunol. 2023;14:1124066. https://doi.org/10.3389/fimmu.2023.1124066</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6(1):e000336. https://doi.org/10.1136/lupus-2019-000336</mixed-citation><mixed-citation xml:lang="en">Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6(1):e000336. https://doi.org/10.1136/lupus-2019-000336</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Xia C, Anderson P, Hahm B. Viral dedication to vigorous destruction of interferon receptors. Virology. 2018;522:19-26. https://doi.org/10.1016/j.virol.2018.06.017</mixed-citation><mixed-citation xml:lang="en">Xia C, Anderson P, Hahm B. Viral dedication to vigorous destruction of interferon receptors. Virology. 2018;522:19-26. https://doi.org/10.1016/j.virol.2018.06.017</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
